Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on PAVmed but lowers the price target from $22 to $21.

September 10, 2024 | 9:31 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on PAVmed but lowers the price target from $22 to $21.
The analyst's decision to maintain a Buy rating suggests continued confidence in PAVmed's potential, but the slight reduction in the price target indicates a more cautious outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100